Cenobamate is a novel antiepileptic that reduces neuronal excitability through sodium-channel modulation and positive allosteric GABA-A modulation at a distinct benzodiazepine-independent binding site, used as adjunctive treatment for focal-onset seizures. Simson Pharma's Cenobamate reference standard and impurities support stability-indicating method development for this newer-generation antiepileptic.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Cenobamate Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.